报价延迟最少15分钟:2025/07/14 18:36 EDT
盘后时段
|
||||
|
0.5908 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6045
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.25/-0.26
|
|
企业价值
99.80M
|
| 资产负债 |
|
每股账面净值
0.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.89M
|
|
每股收益
0.10
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/14 18:36 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions. |
